Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

BACKGROUND: Immune checkpoint inhibitors (ICIs) are approved to treat multiple cancers. Retrospective analyses demonstrate acceptable safety of ICIs in most patients with autoimmune disease, although disease exacerbation may occur. Psoriasis vulgaris is a common, immune-mediated disease, and outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Halle, Briana Rose, Betof Warner, Allison, Zaman, Farzana Y, Haydon, Andrew, Bhave, Prachi, Dewan, Anna K, Ye, Fei, Irlmeier, Rebecca, Mehta, Paras, Kurtansky, Nicholas R, Lacouture, Mario E, Hassel, Jessica C, Choi, Jacob S, Sosman, Jeffrey A, Chandra, Sunandana, Otto, Tracey S, Sullivan, Ryan, Mooradian, Meghan J, Chen, Steven T, Dimitriou, Florentia, Long, Georgina, Carlino, Matteo, Menzies, Alexander, Johnson, Douglas B, Rotemberg, Veronica M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506877/
https://www.ncbi.nlm.nih.gov/pubmed/34635495
http://dx.doi.org/10.1136/jitc-2021-003066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506877/
https://www.ncbi.nlm.nih.gov/pubmed/34635495
http://dx.doi.org/10.1136/jitc-2021-003066

Ejemplares similares